New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.

Impressive clinical benefits have been derived by inhibiting the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors. There is growing evidence that aldosterone plays a contributing role in the pathogenesis of heart failure beyond its sodium retention properties. EPHESUS, a trial of a novel aldosterone antagonist, eplerenone, in patients with myocardial infarction, left ventricular dysfunction and pulmonary congestion will determine whether this approach produces additive clinical benefits in modernly managed patients.